[Pulmonary MALT lymphoma with macroglobulinemia]. 2005

Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
Department Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine.

An 84-year-old man was diagnosed as having pulmonary MALT lymphoma in January 1997. Six years later, he was admitted to our hospital with coughing and dyspnea in November 2003. Dissemination of MALT lymphoma was confirmed by findings of pleural effusion and bone marrow aspiration. A FISH analysis of cells from the pleural effusion revealed t(11;18)(q21;q21) and the serum level of IgM was 8,600 mg/dl (M-protein). The diagnosis of secondary macroglobulinemia was made. The patient received rituximab monotherapy because he was very elderly. Pleural effusion has not been seen after the administration of rituximab, although there have been no changes in the lung mass and serum values of M-protein.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008258 Waldenstrom Macroglobulinemia A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity. Lymphoma, Lymphoplasmacytoid,Macroglobulinemia,Familial Waldenstrom's Macroglobulinaemia,Lymphoma, Lymphocytic, Plasmacytoid,Primary Macroglobulinemia,Waldenstrom's Macroglobulinaemia,Waldenstrom's Macroglobulinemia,Familial Waldenstrom Macroglobulinaemia,Familial Waldenstroms Macroglobulinaemia,Lymphomas, Lymphoplasmacytoid,Lymphoplasmacytoid Lymphoma,Lymphoplasmacytoid Lymphomas,Macroglobulinaemia, Familial Waldenstrom's,Macroglobulinaemia, Waldenstrom's,Macroglobulinemia, Primary,Macroglobulinemia, Waldenstrom,Macroglobulinemia, Waldenstrom's,Waldenstrom Macroglobulinaemia,Waldenstrom's Macroglobulinaemia, Familial,Waldenstroms Macroglobulinaemia,Waldenstroms Macroglobulinemia
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
January 2019, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
November 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
April 2014, Journal of the Formosan Medical Association = Taiwan yi zhi,
Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
March 1999, Leukemia,
Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
April 2002, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
October 2007, La Revue du praticien,
Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
February 2014, Bulletin du cancer,
Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
April 2024, Methods (San Diego, Calif.),
Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
January 2022, Respiratory medicine case reports,
Hirotaka Takasaki, and Maki Takabayashi, and Satoshi Yamaji, and Hideyuki Koharazawa, and Katsumichi Fujimaki, and Heiwa Kanamori, and Yoshiaki Ishigatsubo
February 2024, Archivos de bronconeumologia,
Copied contents to your clipboard!